Skip to content

Exploring the efficacy of Jichuan Decoction in treating post-stroke constipation patients and its effect on the occurrence of cerebrovascular adverse events based on the microbiota-gut-brain axis and the MAPK signalling pathway

Exploring the efficacy of Jichuan Decoction in treating post-stroke constipation patients and its effect on the occurrence of cerebrovascular adverse events based on the microbiota-gut-brain axis and the MAPK signalling pathway

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085126
Enrollment
Unknown
Registered
2024-05-31
Start date
2024-06-01
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-stroke constipation

Interventions

Experimental group :Administer traditional Chinese medicine Jichuan Decoction orally, 1 dose per day, decoction in water, 300ml in water, 2 times per day, 150ml per time
Control group:Administer 15-30ml of lactulose oral solution orally once a day

Sponsors

Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) It meets the diagnostic criteria for stroke (Chinese Guidelines for the Primary Prevention of Cerebrovascular Disease), the Western medical diagnostic criteria for constipation (Rome IV) and the diagnostic criteria for constipation of the Chinese medicine yang-deficiency type (Guidelines for the Diagnosis and Treatment of Constipation), and is currently in stable condition. (2) Age above 45 and below 75. (3) Informed consent and able to co-operate with the return visit. (4) Comply with the TCM evidence identification of Yang deficiency.

Exclusion criteria

Exclusion criteria: (1) Those who cannot co-operate with return visits (2) Patients with massive cerebral infarction; (3) Swallowing dysfunction, unable to take care of themselves; (4) Puddle water test greater than grade 3; (5) Other diseases that seriously affect the quality of life: malignant tumour, acute myocardial infarction, heart failure, uremia, etc.

Design outcomes

Primary

MeasureTime frame
intestinal flora;functional nuclear magnetic resonance imaging ;serum metabolomics;constipation symptom score;swallowing function;physical function;language function;Efficacy of Traditional Chinese Medical Treatment;MAPK signalling pathway-related proteins;

Secondary

MeasureTime frame
ELISA;

Countries

China

Contacts

Public ContactGu Jinhui

Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine

dr.gjh@163.com+86 180 5173 1327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026